Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Market confidence in the sector has improved, helping him to win the backing of institutional investors including Henderson, Aviva and, most recently, Neil Woodford. They spend time and money to gain the insights that give them the edge over rivals in the market and tell them when to buy and when to sell.
Silence Therapeutics Private investors stake their dreams on risky biotech start-ups 19th April 2015 http://goo.gl/reJr9X
What happened to all the other messages ? Why is SLN not trading today ?
although there is always a risk in pharma shares, SLN price is still at a fairly low price, and worth a punt
price now 275 GL
will be some profit taking today by those wanting short term gains, but suggest that the longer haul will provide the greatest return.
provides a draft interim analysis of Atu027-I-02 Phase IIa study in pancreatic cancer. The primary objective of this trial was to assess safety and pharmacokinetics, and the secondary objective was to evaluate efficacy, including Progression Free Survival (PFS). This study was open label in 23 patients with incurable pancreatic cancer and included two treatment arms with Atu027 in combination with the standard of care, gemcitabine. Treatment arm 1 delivered one dose per week for three weeks, followed by one week of no treatment, giving a total of 6 administrations in 8 weeks. Treatment arm 2 delivered 2 doses per week during 4 weeks, followed by 4 weeks of no treatment, a total of 8 administrations in 8 weeks. Arm 2 therefore received 33% more Atu027 during the same treatment period. The presented results are preliminary but have been generated by an independent clinical research organisation. Tolerability and platform validation There was no difference in safety events leading to discontinuation between the two arms, with one subject withdrawing because of an adverse event in each arm. Atu027 was generally well tolerated. In addition, the study results are an important further validation of Silence's two-component drug -a short interfering RNA (siRNA) and a delivery system. Over 400 patients have now been treated with the Company's proprietary modified siRNA (AtuRNAi®), with excellent tolerability. In regards to delivery, this data gives further evidence of the favourable safety profile of Silence's delivery platforms, which are the core components of the Company's 'multiple shots at goal' strategy. Progression free survival A preliminary analysis of this open label study indicates that the subjects who were exposed to a 33% higher total dose of Atu027 had a longer duration of PFS (median of 5.33 months) than patients on the lower exposure regimen (median of 1.81 months). This suggests that in this study, a dose-dependent effect was seen for Atu027. Ali Mortazavi, CEO of Silence Therapeutics, said: "Even allowing for the small number of patients in the trial, these results show a clear signal which requires further investigation. Atu027 has the potential to become a new therapeutic modality in oncology. This is an excellent outcome both in terms of Atu027 and validation of our RNA therapeutics platform. In light of this data, we are reviewing the protocol for the planned Phase Ib head and neck cancer study. "In addition to the clinical development of Atu027, Silence Therapeutics has a wide range of pre-clinical projects based on its ability to modulate gene expression both on and off. We look forward to the future with great confidence."
Will Alnylam Pharmaceuticals have to ask silence therapeutics for a RNAi trigger license for all of its therapeutics. This could be expensive for Alnylam Pharmaceuticals (the leader in the field, $9.8B market cap) and very lucrative for silence therapeutics! Milestones and royalties :), see the link http://rnaitherapeutics.blogspot.fi/2015/03/alnylams-scientifically-dishonest.html
on second-phase clinical trial for ATu027 middle of year? Still time to buy in at low price.
Good news about the Euro patent be approved!
happening at the end of Tuesday, quite a few small buys going through??
FD Tim Freeborn will present at the first Proactive One2Onw forum of 2015 at the Chesterfield on 15th January; http://tinyurl.com/o2zb2gt
Anyone noticed the near 200% gain according to top rises food this is money from today?
This has been months in rhe making, big news should break very very soon
And no comments?
Seems that it's not a matter of interest ;) But with a senior board resignation, vague results from quark, and a "capital markets presentation" due, I'm not surprised.
Can anyone tell me what 220 is in old money Is it 4p? Gosh this thread is quiet
QPI-1002 misses the phase II predefined 30% improvement (only 15%), except in subgroups. It is unsure if they will go through to pIII. Still it shows that silence therapeutics core chemistry/products do something. Quark only used naked siRNA, whereas silence use lipid coating which should improve the effect. http://www.fiercebiotech.com/story/quarks-rnai-treatment-misses-mark-phase-ii-kidney-trial/2014-07-29
Here is new poster of Atu111 (siRNA against Ang2) in lung sepsis which silence are developing. It looks promising. http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCIQFjAA&url=http%3A%2F%2Fsilence-therapeutics.com%2Fwp-content%2Fuploads%2F2011%2F12%2FPoster-GRC-Ang2-siRNA.pdf&ei=t_vXU727GOvNygOu24HoBA&usg=AFQjCNFZ8c_ORb7-cCCOl-SIk6fgCaWK6Q&sig2=YEd0R23TZAmB1Hr9pXGl2w&bvm=bv.71954034,d.bGQ&cad=rja
World Transplant Congress 2014 Abstract for QPI-1002 from licence Quark pharma (which Silence ther. gets royalties from) looks to be positive for phase 2 according to the congress abstract. Abstract# 2967. http://onlinelibrary.wiley.com/doi/10.1111/ajt.12880/pdf Royalty and milestone deal details are not announced. It could be as high a £4M milestone upon entering phase 3. If the agreement is similar to Quarks other licensed siRNA PF-655 with Silence ther.
1.36 mill trade today - someone knows something!!
heading to £3 in sight
.